Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.47 |
| ▸ | NPY1R | P25929 | 6/20 | 0.47 |
| ▸ | NPY2R | P49146 | 4/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 1/20 | 0.37 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8742594 | 0.95 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL30121066 | 0.95 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL30422560 | 0.95 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL29378646 | 0.95 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL31376472 | 0.95 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL30423395 | 0.95 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL8742615 | 0.95 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL10944182 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL10940273 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RGNAI3 | |
| SCHEMBL10942024 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | JACOB GARY S | 2006-05-18 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0506628-B1 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | SIGMA TAU IND FARMACEUTI (IT) | 1996-09-18 | — | — | EP | claimed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | claimed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | claimed |
| JP-5117275-A | — | — | None | — | — | JP | disclosed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2025083437-A1 | THE USE OF TP3 (THYMOPENTIN ANALOG) BY INCREASING THE ACTIVITY AND NUMBER OF T-CELLS INVOLVED IN THE DEFENSE MECHANISM OF THE IMMUNE SYSTEM OF MAMMALS, FOR THE PREVENTION OR TREATMENT OF DISEASES TO EXTEND THE AVERAGE LIFESPAN | DENES LASZLO (HU) | 2025-04-24 | — | — | WO | disclosed |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240228662-A9 | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-11 | — | — | US | disclosed |
| EP-0506628-A3 | AMINOACYL AND OLIGOPEPTIDYL DERIVATIVES OF ALLOPURINOL EXHIBITING IMMUNOSTIMULATORY ACTIVITY, AND PHARMACEUTICAL FORMULATIONS CONTAINING THESE SUBSTANCES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-10-21 | — | — | EP | disclosed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| EP-0506628-A2 | Aminoacyl and oligopeptidyl derivatives of allopurinol exhibiting immunostimulatory activity, and pharmaceutical formulations containing these substances | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
| EP-0464009-A2 | Oligopeptide derivatives of ipoxantine endowed with immunomodulating activity and pharmaceutical compositions containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | NPY4R 630/4885NPY1R 709/4885NPY2R 736/4885 |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | NPY4R 1392/4885NPY1R 1687/4885NPY2R 2126/4885 |
| US-20060106065-A1 | Methods of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D- glucuitol compounds in combination therapy | HAVCR2, DERA, UGGT1 | NPY4R 4158/4885NPY1R 4352/4885NPY2R 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.